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Abstract
Background With tumor necrosis factor inhibitors, chan-
ges of dosing, switching between drugs, insufficient
adherence, and persistence are frequent in rheumatoid
arthritis. Because this is often associated with decreased
efficiency and increased costs, dosage analyses based on
claims data are of increasing interest for healthcare pro-
viders and payers. Nevertheless, no standardized methods
exist to ensure high-quality research.
Objective In this review, we compare and discuss applied
methods in claims data-based dosage analyses of tumor
necrosis factor inhibitor prescriptions in patients with
rheumatoid arthritis.
Methods A systematic review was performed in accor-
dance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statement. The dosage
analysis methods performed within the selected studies
were classified into switching, persistence, adherence, and
dosage-change analyses, and were then compared and
finally discussed.
Results A total of 45 studies were found to be relevant. In
most studies, a change in dose or persistence was evalu-
ated, followed by switching and adherence analyses.
Analyses of changed dose exhibit the most extensive
variation of methods. We divided them into three principal
methods, where a specified reference dose is compared
with (1) the last dose, (2) any dose, or (3) all doses.
Conclusion The systematic review identified a high vari-
ation of methods. Our results may be helpful for choosing
appropriate methods in future studies. The results also
demonstrate the need for evidence-based recommendations
of methods used in claims data research.
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Key Points
Dosage analyses of switching differ with respect to
the implementation of a time frame and with respect
to controlling the discontinuation of the previous
therapy.
Dosage analyses of persistence are characterized by
the criteria used for therapy discontinuation. These
are allowance of switching to other treatments and
the therapy discontinuing prescription gap.
Proportion of days covered and the medication
possession ratio with fixed or variable follow-ups are
the most frequently used methods for claims data
analyses of adherence.
Dosage change analyses exhibit the most extensive
variation of methods. They differ with respect to the
type of dose comparison and with respect to other
restrictions that are necessary to define a dose
escalation or a decrease in dose. These restrictions
refer for example to the length of prescription
intervals and to the difference between a changed
dose and its reference.
We divide changes in dose into three principal
methods: a comparison of (1) the last dose, (2) any
dose, or (3) all doses to a specified reference dose.
Reference doses are the index, maintenance,
recommended, and previous dose.
1 Introduction
Tumor necrosis factor (TNF) inhibitors are substantial
components in the management of patients with rheumatoid
arthritis (RA). RA is a systemic, inflammatory, chronic
autoimmune disease of the peripheral joints. It leads to joint
swelling and pain with decreasing mobility. The messenger
substance TNF-a triggers the inflammatory process of RA.
Because TNF-inhibitors are able to block TNF-a itself or the
receptors of the target cells, they can influence the inflam-
matory process directly, reduce the progression of the dis-
ease, and improve symptoms [1]. Inadequate compliance or
adherence to therapy could complicate the therapeutic suc-
cess and cause higher therapy costs [2]. TNF inhibitors are
costly and changes in prescription may significantly impact
healthcare costs [3, 4]. Therefore, investigating changes in
therapy is important to patients, healthcare providers, and
healthcare payers. Because claims data analyses allow for
insight into drug prescriptions under real-life conditions,
they are powerful instruments for evaluating healthcare
provision [5].
High-quality research is needed to provide good evidence
on comparative drug dosing analyses in real life, but there are
no standardized methods available. No systematic review
has been conducted that classifies and compares methods
used in studies reporting dosage analyses of TNF inhibitor
prescriptions in patients with RA on the basis of claims data.
Therefore, the objective of the present study is to provide
such a review, comparing the methods used in switching,
persistence, adherence, and dosage-change analyses.
Finally, the resulting findings may provide guidance for the
most appropriate application of the methods in future
research and contribute to evidence-based recommendations
for dosage analyses with claims data.
This review is structured as follows: first, we present the
methodology of our review, comprising the eligibility cri-
teria, the search strategy, and the handling of outcomes and
data. Second,we present an overviewof the identified studies
and their characteristics, followed by classification of their
methods.We endwith a discussion of the identifiedmethods.
2 Methods
To identify the relevant literature, a systematic review
following the guidelines of the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses statement was
conducted on February 12, 2016. First, the selection criteria
were defined. Second, a systematic search, based on these
selection criteria, in the MEDLINE, BIOSIS Previews,
EMBASE Alert, EMBASE, German Medical Science—
Journals and Meetings and SciSearch databases, provided
by the German Institute for Medical Documentation and
Information [6] platform, was performed. Search terms
used corresponded to the indications (RA), the intervention
(TNF inhibitors), claims data, and dosage analyses, as well
as their results, such as changes in dose, switching,
adherence, and discontinuation. Synonyms for each term in
either the German or the English language were used. Sub-
searches for each search term were applied and finally
combined. The full search code can be provided on request.
From the identified literature, the relevant studies were
selected based on the following inclusion criteria:
1. Studies must be full publications written in either the
German or the English language.
2. The study population must include at least one
subgroup of RA patients.
3. The analyses must be based on claims data.
4. The course of drug therapy, such as switching drugs,
changes in dosage, adherence, or persistence, must be
investigated.
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5. The therapy must involve at least one TNF inhibitor.
6. The dosage analyses must be an essential part of the
study, meaning outcomes of the dosage analyses must
be reported.
The comparison of methods is basically a comparison of
different claims data-based definitions of the various out-
comes. To this end, the identified studies were classified
into their outcomes of the switching, adherence, persis-
tence, and dosage-change analyses.
Switching analysis was classified based on the time
frame and information on whether discontinuation of the
former drug was ensured. The time frame is the gap
between the last prescription of the former drug and the
new one that is allowed at maximum, before a therapy is
considered to be terminated.
We use the terms persistence and adherence in accor-
dance with the International Society of Pharmacoeco-
nomics and Outcome Research because the terms
adherence and persistence are not used consistently in the
identified literature [7]. According to the International
Society of Pharmacoeconomics and Outcome Research,
persistence describes the duration of continuous treatment.
Methods of persistence analyses are classified by the
maximum time frame allowed and information on whether
a switch between drugs within a drug class was accepted.
The time frame is the maximum prescription gap that was
still allowed between two prescriptions to assume persis-
tency. Otherwise the therapy was considered to be
terminated.
In contrast to persistence, adherence is a measure of the
extent to which a patient adheres to his/her treatment as
recommended or prescribed. It is typically bound to a value
between 1 and 0, where 1 indicates perfect adherence, and
0 indicates no adherence. We classified adherence analyses
based on the measure of adherence that was used in the
identified literature.
A changed dose is deemed as either an increase or
decrease in prescription dose. For dosage change analyses,
we defined three principal methods based on the type of
doses that were compared. These are (1) the last dose vs.
reference, (2) any dose vs. reference, and (3) all doses vs.
reference. In studies being selected to category (1), any
change or a certain minimum change of the last prescrip-
tion dose within the follow-up, compared with a reference
dose was defined as a dose escalation or dose reduction. In
category (2), all doses within the study period were com-
pared with a reference. If any change in dose, as defined in
the corresponding study, can be observed, the associated
patient was flagged as having had a dose escalation or dose
reduction. In category (3), mean doses of all prescriptions
within a certain period were calculated and compared with
a reference. The periods chosen varied.
A quantitative assessment of quality, in terms of validity
and sensitivity, exceeds the scope of this review and should
be subjected to further research.
3 Results
3.1 Search Results
The process of selecting references included in this review is
shown in Fig. 1. After excluding duplicates and articles not
complying with the inclusion criteria, 45 studies were
included in the present review. An overview of the selected
publications is given in Table 1. In most studies, treatment
with adalimumab (ADA), etanercept (ETN), and/or inflix-
imab (IFX) was evaluated. Because golimumab (GLM) and
certolizumab pegol (CP) have only been available since
2009, there are only a few dosage analyses available in recent
studies. No study analyzing dosing of biosimilars was found.
In most studies, the change in dose (n = 27) or persistence
(n = 26) was evaluated, followed by switching analyses
(n = 20). Adherence was only investigated in 14 studies.
The claims data of the studies identified were mostly gen-
erated from different US databases. Only four of them used
Korean, Swiss, German, or Italian claims data [4, 8–10].
3.2 Definitions of Switching, Persistence,
and Adherence
3.2.1 Switching
Switching of therapy influences persistence because it
often terminates the current treatment. Available studies
explored either switching or they attempted to analyze
characteristics of subgroups of people who switched drugs
[11]. A switch is defined as a change between certain
medications. Some studies defined a maximum time frame
of various lengths between the last prescriptions of the
former drug and the prescription of the new drug. The
switch needs to take place within that frame, otherwise the
therapy is considered to be terminated. Some studies also
indicated if they had ensured the discontinuation of the
former drug to avoid confusing co-medication with
switching. The various definitions applied are shown in
Table 2.
The termination of the previous therapy was assured in
five studies [8, 9, 12–14]. Most studies did not make any
statement regarding termination of previous therapy. A
maximum time frame was rarely specified. The length of
this period mostly depends on the days of supply (DOS)1 of
1 DOS are either given in the claims data or they refer to the expected
prescription interval.
Dosage Analysis Methods for TNF Inhibitors in RA 267
the last prescription of the former medication plus an
additional period of 30 or 90 days [9, 13, 15]. In one case, a
time frame of 200 % of the prescribed index-DOS was
chosen instead [16]. In contrast, in four cases, a time frame
was not required [17–20]. It should be noted that most
studies did not indicate whether or not a time frame was
implemented.
3.2.2 Persistence
A therapy is terminated either if a switch to another med-
ication occurs or the time frame, meaning the gap between
two prescriptions, gets too large. Table 3 lists the allowable
switches between medications and which time frames were
accepted for the assumption of persistency. With the
exception of Curkendall et al., who evaluated persistence
for several drugs simultaneously, no other authors explic-
itly allowed a switch in medication [21]. The accepted gap
between two prescriptions mostly depends on DOS or the
expected dosing intervals plus a further period of
30–90 days. Expectations are usually drawn from the
therapy recommendations. In contrast, a fixed maximum
period was defined in six studies [8, 19, 20, 22–24].
3.2.3 Adherence
Adherence is sometimes difficult to evaluate in claims
datasets because most TNF inhibitors are injected by the
patients themselves, and thus detailed information is
missing in the database. This is not the case with IFX,
which is by intravenous (i.v.) application in a clinical set-
ting. Therefore, this is registered in the claims data. In
either case, it can be observed whether the prescriptions are
refilled within DOS-supplied or within recommended
intervals. Thus, the fraction of days with medication on
hand can be determined, which is fundamental for the
calculation of measures of adherence.
For the most part, adherence was examined with ratios
such as the medication possession ratio (MPR)
[2, 12, 21, 22, 25–28], the proportion of days covered
(PDC) [13, 22, 23, 28, 29], or the compliance ratios of
Harley et al. or Tkacz et al. [30, 31]. In contrast to the
MPR, which equals the sum of DOS divided by the treat-
ment period, the PDC considers the days with DOS
available to the patient by taking the storability of drugs
into account.
The MPR was calculated for fixed [2, 25] or variable







where Tf indicates the follow-up. Variable follow-ups
depend on individual treatment periods. The treatment
usually starts with the index date, the date of the first
prescription and ends with the end of study period or with
the termination of the treatment, whereas fixed follow-ups
are the same for all patients. In that case, the length of the
follow-up is specified ex ante. Only patients who are
persistent within that period are analyzed. With fixed
687 records identified through 
database searching




386 of records excluded
63 records of full-text articles assessed for eligibility
18 records excluded due to criterion 
no.3 (no claims data): 2 records
no.4 (no analysis of the course of therapy): 8 records
no.5 (no TNF-inhibitor): 3 records
no.6 (no reported outcomes): 5 records
45 records included in analysis of methods
Fig. 1 Process of selection
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Table 1 Overview of selected publications according to the prescribed TNF inhibitors and the mode of change in dosing





Source of claims data
IFX ADA ETN GLM CP S P A C Provider Country
Harley et al. [30], 2003 x x x x A large health plan USA
Gilbert et al. [38], 2004 x x x IMS PharMetrics USA
Berger et al. [32], 2005 x x Constella USA
Etemad et al. [42], 2005 x x x A large health plan USA
Ollendorf et al. [46], 2005 x x IMS PharMetrics USA
Weycer et al. [11], 2005 x x x Constella
Ingenix LabRx
USA
Grijalva et al. [12], 2007 x x x x x x Tenessee Medicaid USA
Curkendall et al. [21], 2008 x x x x MarketScan USA
Tang et al. [47], 2008 x x x x x IMS PharMetrics USA
Wu et al. [34], 2008 x x x x x Ingenix employer database USA
Borah et al. [2], 2009 x x x x A large health plan USA
Nair et al. [43], 2009 x x MarketScan USA
Ollendorf et al. [33], 2009 x x x x IMS PharMetrics USA
Yazici et al. [15], 2009 x x x x x x IMS PharMetrics USA
Gu et al. [48], 2010 x x x x MarketScan USA
Harrison et al. [3], 2010 x x x x x IMS PharMetrics USA
Huang et al. [41], 2010 x x x MarketScan USA
Li et al. [13], 2010 x x x x x Medicaid Analytic Extract USA
Ogale et al. [17], 2011 x x x x x x Optum Insight USA





Bonafede et al. [49], 2012 x x x x x MarketScan USA
Cho et al. [8], 2012 x x x x x Korea National Health
Insurance claims database
Korea
Nguyen-Khoa et al. [50], 2012 x x x x MarketScan USA
Thyagarajan et al. [51], 2012 x x x x x Optum Insight USA
Zeidler et al. [4], 2012 x x x x x Helsana Health Insurance Switzerland
Blume et al. [44], 2013 x x x x Medco USA
Chastek et al. [37], 2013 x x x x Optum Insight USA
Fisher et al. [39], 2013 x x x x x x HIRD USA
Johnston et al. [18], 2013 x x x x MarketScan USA
Curtis et al. [25], 2014a x x x x x x x IMS PharMetrics USA
Curtis et al. [26], 2014b x x x x x x x MarcetScan USA
Howe et al. [14], 2014 x x x x x x x Humana Health Insurance USA
Joyce et al. [36], 2014 x x x x x IMS LifeLink USA
Meissner et al. [16], 2014 x x x x IMS PharMetrics USA
Neubauer et al. [9], 2014 x x x x x x DAK Health Insurance Germany
Oladapo et al. [27], 2014 x x x x x x Texas Medicaid USA
Tkacz et al. [22], 2014 x x x x x Optum Insight USA
Wu et al. [24], 2014 x x x x x x x Medco USA
Bonafede et al. [23], 2015 x x x x x x x x x MarketScan USA
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follow-ups, the end of the follow-up can be exceeded by
DOSL, which is the DOS of the last prescription. That
happens when the study period ends before the DOS of the
last prescription are used. Therefore, Borah et al. truncated
the exceeding DOS to avoid overestimating adherence [2].
In the case of variable follow-ups, the follow-up either ends
with the last prescription plus DOSL, when all DOS are
used, or at the date of the last prescription. The former was
usually performed, whereas the latter was used by Grijalva
et al., who excluded the exceeding DOSL from the MPR







where T indicates the whole study period.
All MPRs can get larger than 1 if more prescriptions are
filled than are needed. In such cases, Tkacz et al. normal-
ized the MPR to 1 [22]. This is not necessary with the PDC
because it avoids double counting the days where daily
doses are on hand [13]. In five studies, PDCs are reported
[13, 22, 23, 28, 29]. Thereof, two studies lacked a precise
definition of the PDC calculation. Thus, their methods are
not described here [22, 29]. Li et al. [13] gave a very
precise description of the PDC. Their method is shown in
Figs. 2 and 3. In the case of the subcutaneous (s.c.)
application of TNF inhibitors by the patient, the provided
syringes are storable (Fig. 2). Therefore, DOS of pre-
scription V1 exceeding the date of the next prescription V2
can be added to the DOS of prescription V2. In contrast,
IFX is administered in a clinical setting. Therefore, DOS
exceeding the next prescription are not storable (Fig. 3)
and premature administration of i.v. drugs does not extend
the next expected prescription interval. That is why Li et al.
[13] used different procedures for calculating the days with
drugs on hand for s.c. and i.v. TNF inhibitors, respectively.
Because of the storability of s.c. drugs, the remaining DOS
from a previous prescription are added to the following
DOS, plus the day of the new prescription, for which
adherence can be assumed (Fig. 2). DOS of i.v. and s.c.
drugs exceeding the end of the study are excluded. The
remaining gap equals the days without medication on hand
Table 1 continued





Source of claims data
IFX ADA ETN GLM CP S P A C Provider Country
Curtis et al. [28], 2015 x x x x x x x x Optum Research USA
Johnston et al. [20], 2015 x x MarketScan USA
Sangiorgi et al. [10], 2015 x x x x x x Health-Assisted Subjects Database Italy
Tkacz et al. [31], 2015 x x x Optum Insight USA
Zhang et al. [29], 2015 x x x x x Medicare USA
Harnett et al. [19], 2016 x x x x x x x MarketScan USA
Total 40 34 39 9 5 20 26 14 27
ADA adalimumab, CP certolizumab pegol, ETN etanercept, GLM golimumab, HIRD HealthCore Integrated Research Database, IFX infliximab,
PPD Premier Perspective Database, TNF tumor necrosis factor, WKPS Wolters Kluwer Pharma Solutions, x applied in analysis
Table 2 Definitions of switching
Time frame Discontinuation ensured?
Yes Not specified
Not specified Cho et al. [8] Bonafede et al. [49]
Nguyen-Khoa et al. [50]
Thyagarajan et al. [51]
Fisher et al. [39]
Curtis et al. [25]
Curtis et al. [26]
Neubauer et al. [9]
Oladapo et al. [27]
Wu et al. [24]
Bonafede et al. [23]
Curtis et al. [28]
No time frame Harnett et al. [19] Ogale et al. [17]
Johnston et al. [18]
Johnston et al. [20]
30 days ? DOS Yazici et al. [15]
45 days Howe et al. [14]
90 days ? DOS Grijalva et al. [12]
Li et al. [13]
200 % 9 DOSindex Meissner et al. [16]
DOS days of supply, DOSindex DOS of index prescription
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[7]. Curtis et al. and Bonafede et al. used a similar tech-
nique, where they limited the added period in s.c. TNF
treatment to a maximum of 14 days [23, 28]. Finally, they
calculated the PDC for s.c. and i.v. drugs by dividing the
days with medication on hand by the time of follow-up
[13].
Another measure of adherence is the compliance ratio,
used by Harley et al., as well as by Tkacz et al., for
injections and infusions alike. It is the ratio between the
number of actual and expected prescriptions within a per-
iod [30, 31]. It can be larger than 1 if more prescriptions
are filled than what was expected.
Although the reported measures of adherence are con-
tinuous, it is frequently reported as a binary variable
[2, 13, 22, 23, 28–30]. To this end, a threshold for ratios,
for example of 80 %, is specified, beyond which a patient
is considered to be adherent [2, 13, 23, 25, 28–30]. In one
study, adherence is not defined as a continuous measure,
Table 3 Criteria used to
describe persistence of
medication
Time frame Switch allowed?
Yes No Not specified
Not specified Harrison et al. [3]a
Sangiorgi et al. [10]
Tang et al. [47]
30 days ? DOS Borah et al. [2]
Yazici et al. [15]b
Thagarajan et al.
[51]
31 days ? DOSc Curkendall et al.
[21]
45 days Wu et al. [24]
45 days ? DOS Bonafede et al. [49]d
Fisher et al. [39]
Howe et al. [14]
60 days ? DOS Zeidler et al. [4]
Blume et al. [44]
Joyce et al. [36]a
Neubauer et al. [9]e
Wu et al. [34]
61 days ? DOSc Ogale et al. [17]f
73 days Bonafede et al. [23]g




90 days ? DOS Grijalva et al. [12]
Li et al. [13]h
Zhang et al. [29]
Tkacz et al. [31]
90 days ? usual dosing interval Zhang et al. [29]
14 weeks Cho et al. [8]
180 days Harnett et al. [19]
110 % of expected dosing
interval ? DOS
Tkacz et al. [31]
ADA adalimumab, DOS days of supply, ETN etanercept, IFX infliximab, s.c. subcutaneous
a Switchers were excluded from the analysis
b Method of DOS calculation is not explicitly given
c The day of prescription is added to the DOS
d DOS ETN = 7 days for a 50-mg syringe; DOS ADA = 14 days for a 40-mg syringe; DOS
IFX = 56 days for one infusion
e Subgroup analyses for switcher and non-switchers; sensitivity analyses with gaps of 30, 60, and 120 days
f Sensitivity analysis for gaps of 180 days
g For s.c. drugs, an overlay up to 14 days is added
h Sensitivity analysis for gaps of 30, 60, and 120 days
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although the MPR and the PDC are reported. Instead, the
authors defined a new prescription as adherent if it is filled
within 21–38 days after the previous one [22]. Similarly,
Curtis et al. defined i.v. therapy as adherent if the number
of infusions at least equals the expectations [25–28].
Tkacz et al. also used other novel measures of adherence
for infusions based on infusion gaps above expectations
and on the number of infusions because DOS were not
available for these agents [31]. They accumulated treat-
ment gaps, which are defined as the difference between
observed and expected infusion intervals. These gaps were
categorized as those that are at least 20 % above expec-
tation on those that do not increase expectation by any
amount. They also identified variations in adherence by
observing the occurrence of different predefined categories
of gaps within a treatment period. Another measure of
adherence was defined as the number of infusions in 1 year
with gaps of at least 10 % above the expected interval [31].
3.3 Changes in Dosage
Changes of prescribed doses can lead to decreases or
increases in daily dose. Sometimes, changes exceeding or
falling below a certain threshold are required to define an
increased or decreased dose. A dosage complying with a
definition like that is also called dose escalation. In all
studies considering dosage changes, dose escalations were
examined. In all, six studies [11, 15, 30, 32–34] considered
reductions and four [11, 15, 33, 34] investigated
stable doses. One study, where reduced doses are calcu-
lated, is not included here because it was missing an
explanation and definition of the term ‘reduced dose’ [29].
A dose has to be compared with a reference dose to
decide whether the dose is changed. As a reference, the
index dose, the recommended dose, or the previous pre-
scribed dose was used. In the identified literature, usually
the first dose after a recommended loading period or the
first stable dose was defined as the maintenance dose
[9, 10, 17, 35–40].
The dose that is compared with the reference dose
usually is the mean daily or mean weekly dose. It is cal-
culated by dividing the absolute prescription dose either by
the DOS prescribed or by the prescription interval (see, for
example [23, 39, 41, 42] and [10, 11]). In all other studies,
the absolute prescription dose was used instead. All but one
study used supplementary definitions for changed doses
[40]. These definitions are based on the prescription
interval or the number of prescriptions within an interval.
3.3.1 Last Prescription
The deviation between the last dose and its reference is
used for i.v. and s.c. drugs. The variations within this
category and the associated studies are shown in Table 4.
As references, the index and the maintenance dose were
used. The maintenance dose is employed for IFX-naı¨ve
patients because of the recommended loading period.
However, with s.c. drugs without a loading period or with
experienced IFX patients, the index dose was used [3, 36].
Nevertheless, three studies used the index dose for IFX-
naı¨ve patients as well [11, 30, 43]. In most cases, any
change in the last dose compared with its reference was
sufficient to define a changed dose. Harrison et al. as well
as Blume et al. required an increase over 10 % for dose
escalation [35, 44]. For IFX and GLM, an increase of the
last dose compared with the index dose of at least 100 mg/
application and 25 mg/week were required in four [25–28]
and three studies, respectively [25, 26, 28].
3.3.2 Any Prescription
The definitions used for any dose compared with its ref-
erence over the follow-up are shown in Table 5. In such a
way, the index, maintenance, recommended, or previous
doses were used. These reference doses were applied to s.c.
V1 V2 V3 V4
end of studyindex date
me
= DOS exceeding next prescripon 
(DOS are stored and added to the DOS of the next prescripon)
= resulng gap without DOS
= prescribed DOS + day of prescripon
Fig. 2 Proportion of days covered according to Li et al. [13] for
subcutaneous drugs. DOS days of supply
V1 V2 V3 V4
end of studyindex date
me
= DOS exceeding next prescripon 
   (DOS are not stored and not added to the DOS of the next prescripon)
= resulng gap without DOS
= expected DOS = recommended prescripon interval
Fig. 3 Proportion of days covered according to Li et al. [13] for
intravenous drugs. DOS days of supply
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injections and infusions alike. In 19 records, any increase
or decrease of a prescription was defined as a dosage
change. In other studies, various minimum thresholds were
defined. These thresholds ranged from 10 to 100 %. Fur-
thermore, some methods require these changes in at least
two consecutive observations [10, 17, 33, 44, 37].
In four studies, no reference for dosage analyses of ADA
and ETN was used [25–28]. These studies are shown in
Table 6. Here, a weekly prescription dose of at least 40 mg
ADA or 100 mg ETN was sufficient for dose escalation.
As opposed to s.c. agents, daily doses are difficult to
calculate with IFX, because for infusions, DOS are not
given in the claims data and appropriate IFX dosage is
dependent on the patient’s weight [16, 45]. Therefore, a
supplementary definition of dose increase with IFX is often
defined with reduced prescription intervals [35, 34, 39, 46]
or an increased number of infusions within a certain period
[17, 25–28, 38] as depicted in Table 7. Sometimes, this
increase must be observed in at least two occasions
[17, 38, 46]. For example, Curtis et al. considered a pre-
scription quantity of more than 120 % of that which was
expected as an increase in dose [25–28]. In other cases,
reductions in the recommended infusions period of
8 weeks [45] to either fewer than 6 or fewer than 7 weeks
was defined as an increase in dose [34, 46, 39].
Wu et al. are the only individuals who defined reduced
doses within this class of methods [34]. They also applied a
particularly complex method to patients who did not start
with the recommended dose [34]. The authors defined a
change in dosage in ADA and ETN therapies from the
healthcare provider’s point of view. They assigned the
mean doses of the treatment of naı¨ve patients into four
dosage categories. Mean doses were calculated differently
according to the prescription gaps. If gaps were small or
negative, the DOS given in the prescriptions were taken as
the denominator. Otherwise, the prescription interval was
used. Accordingly, the prescribed mean dose was used in
the former case, whereas the real mean dose seemed more
appropriate to the authors in the last case. The resulting
dosage categories were applied to define a change in dose
using the first stable dose as a reference. An increase or
decrease in dose was defined as at least two switches to a
higher or lower class, respectively. The first stable dose
was defined as the second prescribed dose if the first and
second doses were the same. If the second and third doses
were equal, the third dose was defined as the first
stable dose. Otherwise, the mean value of the first three
prescribed doses was used. If fewer than three prescriptions
were available, the index dose was used as the reference.
3.3.3 All Prescriptions
With this approach of calculating mean doses, all pre-
scriptions within a certain period are taken into account
(Table 8). The recommended, the index, or the mainte-
nance dose is compared with the mean dose of all pre-
scriptions of a specific period. If the index or maintenance
dose is the reference, it was excluded from the calculation.
Two exceptions are the studies of Zeidler et al. and Fisher
et al. where the maintenance dose was included [4, 39].
Huang et al. determined the mean dose for each period
between the index dose and every following prescription
[41]. To identify a dose escalation, at least two of these
mean values had to be greater than the index dose [41]. As
in the previous methods, a certain threshold was defined in
some studies to determine a changed dose.
4 Discussion
The objective of the present systematic review was to
describe and assess methods in published dosage analyses
of TNF inhibitor therapy of patients with RA based on
claims data. The methods of the identified 45 studies of
relevance were compared and grouped into switching,
adherence, persistence, and dosage-change analyses.
In switching analyses, a certain time frame where
switching must occur was rarely used (Table 2). It should
Table 4 Criteria used for the definition of ‘last prescription’
Change in dose Reference dose
Index dose Maintenance dose
Any Harley et al. [30]
Berger et al. [32]
Weycker et al. [11]
Nair et al. [43]
Harrison et al. [3]
Huang et al. [41]
Joyce et al. [36]
Joyce et al. [36]
10 % Harrison et al. [3]a
Blume et al. [44]
Harrison et al. [3]a
100 mg/application (IFX) Curtis et al. [25]
Curtis et al. [26]
Oladapo et al. [27]
Curtis et al. [28]
25 mg/week (GLM) Curtis et al. [25]
Curtis et al. [26]
Curtis et al. [28]
GLM golimumab, IFX infliximab
a In the case of IFX, the change in dose refers to the absolute pre-
scribed dose, not to the mean daily dose between two prescriptions.
To consider time, a reduction in the length of a prescription interval or
an increased number of infusions is also defined as an increased dose
according to Table 7
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be noted that if a time frame is not used, persistency within
treatment cannot be ensured. Furthermore, if the termina-
tion of the previous treatment is not verified, it is not
possible to differentiate co-medication from switching.
For persistence analyses, the usefulness of a time frame
should be also considered. With very small gaps, patients
who are not 100 % adherent will be considered non-per-
sistent. Given the widely accepted adherence level of
80 %, this assumption seems not to be plausible. However,
very large gaps could overestimate persistence, if persis-
tency is mixed with termination and restart of therapy. To
our knowledge, there is no widely accepted standard for the
length of the time gap in persistence analyses. Therefore,
sensitivity analyses with varying prescription gaps may be
useful.
When the MPR is used, analysts should bear in mind
that the MPR in contrast to the PDC is a simple summation
of DOS divided by the treatment period (Sect. 3.2.3). The
PDC is slightly more complicated to calculate but its
assumptions concerning the storability of different drugs
seem to be more realistic (Figs. 2, 3). With the PDC, days
Table 5 Criteria used for the definition of ‘any prescription’
Change in dose FRQ Reference dose
Index dose Maintenance dose Recommended dose Previous dose
Any change 1 Gu et al. [48]
Harrison et al. [3]
Huang et al. [41]
Bolge et al. [40]
Curtis et al. [25]a
Curtis et al. [26]a
Oladapo et al. [27]a
Curtis et al. [28]a
Ollendorf et al. [46]a
Bolge et al. [40]
Fisher et al. [39]a
Blume et al. [44]
Fisher et al. [39]
Bonafede et al. [23]
Etemad et al. [42]
Any change 2 Gilbert et al. [38]a
Wu et al. [34]a
Ogale et al. [17]a,b
Any change Each fill Yazici et al. [15]
10 % 1 Harrison et al. [3]a
Bonafede et al. [23]c
20 % 2 Ollendorf et al. [33]b
30 % 2 Blume et al. [44]b Ollendorf et al. [33]b
Chastek et al. [37]b
Sangiorgi et al. [10]b
Chastek et al. [37]b
33.33 % 1 Neubauer et al. [9] Neubauer et al. [9]
40 % 2 Ollendorf et al. [33]b
100 % 2 Wu et al. [34]
5 mg/week ETN 1 Etemad et al. [42]
To different class 2 Wu et al. [34]d
ETN etanercept, FRQ frequency, IFX infliximab, i.v. intravenous, s.c. subcutaneous
a In the case of IFX, the change in dose refers to the absolute prescribed dose, not to the mean daily dose between two prescriptions. To consider
time, a reduction in the length of a prescription interval or an increased number of infusions is also defined as increased dose according to Table 7
b The increased doses need to follow one another
c After a first increased dose of s.c. drugs is found, it became the new reference dose. If the paid amount for i.v. drugs increased by 10 %, this
was also defined as dose escalation
d The reference dose is the first stable dose within the first three prescriptions
Table 6 Criteria used for the definition of ‘any prescription’
Change in absolute prescription dose FRQ No reference dose
C40 mg/week (ADA) 1 Curtis et al. [25]
Curtis et al. [26]
Oladapo et al. [27]
Curtis et al. [28]
C100 mg/week (ETN) 1 Curtis et al. [25]
Curtis et al. [26]
Oladapo et al. [27]
Curtis et al. [28]
ADA adalimumab, ETN etanercept, FRQ frequency
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with drugs on hand that exceed the next prescription are
just carried over into the future and not into the gaps in the
past. In contrast to the calculation of the MPR, all DOS
within the follow-up period are taken into account.
Therefore, DOS exceeding the next prescription can offset
prescription gaps in the past as well as in the future. Hence,
the MPR may overestimate persistence, as compared with
PDC.
There is a wide variety of dosage change analyses. The
calculation of ‘last prescription vs. reference’ may be one
of the easiest, but it does not consider interim changes in
doses. In contrast, ‘any dose vs. reference’ takes every
prescription into account. Therefore, it is a very sensitive
method and could overestimate changes in dose, for
example, when the increased prescription is an outlier or
error in the claims data. Therefore, sensitivity analyses
with different methods and varying thresholds could be
conducted or, for definition of dose decrease or escalation,
multiple dosage changes could be required [10, 34, 33, 38].
Because with ‘every dose vs. reference’ the overall pre-
scription mean is compared, the influence of an outlier
could be diminished. However, it should be noted that with
exception of the method of Wu et al., where a new pre-
scription mean after each prescription is calculated, the
Table 7 Supplementary
definition of dose escalation in
case of IFX dosage analyses
Change in prescription interval or number of infusions FRQ Article
Changed prescription interval
Any change from index to last prescription interval 1 Harrison et al. [3]
Prescription interval of\6 weeks 1 Fisher et al. [39]
Prescription interval of\7 weeks 1 Wu et al. [34]
2 Ollendorf et al. [46]
Prescription interval of[ 9 weeks (definition of decreased dose) 1 Wu et al. [34]
Changed number of infusions
Increased number of infusions of[20 % compared with expectation 1 Curtis et al. [25]
Curtis et al. [26]
Oladapo et al. [27]
Curtis et al. [28]
C2 infusions within 7 weeks 2 Gilbert et al. [38]
Ogale et al. [17]
FRQ frequency, IFX infliximab
Table 8 Criteria used for the definition of ‘all prescriptions’
Change Dose of interest: mean dose calculated for the period Reference dose
Index dose Maintenance dose Recommended dose
Any change After reference dose to each subsequent prescription Huang et al. [41]a
Joyce et al. [36]
After reference dose to end of follow-up Joyce et al. [36]
Of the entire follow-up Huang et al. [41]
Joyce et al., 2014 [36]
10 % Of the entire follow-up Fisher et al., 2013 [39] Blume et al. [44]
Fisher et al. [39]
15 % After reference dose to end of follow-up Huang et al. [41]
30 % After reference dose to end of follow-up Huang et al. [41]
Blume et al. [44]
Chastek et al. [37]
33.3 % After reference dose to end of follow-up Wu et al. [34]
Of the entire follow-up Zeidler et al. [4] Wu et al. [34]
Zeidler et al. [4]
50 % After reference dose to end of follow-up Huang et al. [41]
a In comparison to the index dose, the mean weekly dose must be increased at least two times
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course of the dosage over the treatment period cannot be
identified [34].
As reference doses, observable prescription doses within
therapy such as the index dose, maintenance dose, or the
previous dose may be advisable if changes within therapy
should be identified. If treatments should be compared with
treatment recommendations, for example, for guideline
evaluations, a suitable reference dose may be the recom-
mended dose. The interpretation of the index dose depends
on the definition on the patient’s experience. If the study
analyzes treatment-naı¨ve patients, the index dose equals
the initial dose, which is the first treatment dose. Other-
wise, if experienced patients are analyzed or if no loading
period is recommended, the index dose and maintenance
dose could be the same. The loading period is the first
period of the therapy where the maintenance level has not
been reached.
Because of the high impact of dosage on costs and the
impact of the virtue of therapy on adherence, persistence,
and dose, dosage analyses are important for healthcare
payers, healthcare providers, and patients alike. To facili-
tate further claims data-based research in this area, we
present a comprehensive overview and a short discussion
of current methods. Because we did not assess quality of
methods quantitatively, further research in this area is
needed.
The present study is limited to publications in the
English or German languages. Furthermore, a detailed
explanation of the methods used was not provided in every
study. Hence, opportunities for comparison are restricted.
Moreover, most studies are performed with US claims data.
Owing to restrictions in available data, the methods
reviewed in this study may not generalize to every country.
5 Conclusions
This systematic review identified a high variation of
methods used in dosage analyses applied to claims data of
TNF inhibitor treatment among patients with RA. Our
information and suggestions may be helpful for choosing
appropriate methods in future studies and greatly facilitate
further dosage analyses. Additionally, the presented sys-
tematic comparison of methods demonstrates the need for
standardized methodology concerning the design, conduct,
analysis, and reporting of claims data studies in rheuma-
tology. Evidence-based methodology is a prerequisite for
cross-study comparisons and to reliably calculate the
healthcare costs of TNF inhibitors in actual patients with
RA.
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